Golimumab: A novel anti-TNF-α human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Drugs of Today

Volumn 46, Issue 1, 2010, Pages 13-22

  Campàs Moya, Clara ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; LYMPHOMA; NAUSEA; NONHUMAN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

EID: 77951428758     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.1.1444434     Document Type: Review

References (60)

1. Goodnow, C.C., Sprent, J., Fazekas de St Groth, B., Vinuesa, C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435(7042): 590-597 (Pubitemid 40825498)
2. Balagué, C., Kunkel, S.L., Godessart, N. Understanding autoimmune disease: new targets for drug discovery. Drug Discov Today 2009, 14(19-20): 926-934
3. Braun, J., Kalden, J.R. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009, 27(4 Suppl. 55): S164-7.
4. Rozenblit, M., Lebwohl, M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009, 22(1): 56-60.
5. Brennan, F.M., Maini, R.N., Feldmann, M. TNF alpha-a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992, 31(5): 293-8.
6. Victor, F.C., Gottlieb, A.B. TNF-alpha and apoptosis: Implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 2002, 1(3): 264-275.
7. Mease, P.J. Tumour necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002, 61(4): 298-304. (Pubitemid 34257738)
8. Braun, J., Bollow, M., Neure, L. et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38(4): 499-505.
9. Braegger, C.P., Nicholls, S., Murch, S.H., Stephens, S., MacDonald, T.T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339(8785): 89-91.
10. Murch, S.H., Lamkin, V.A., Savage, M.O., Walker-Smith, J.A., MacDonald, T.T. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991, 32(8): 913-917
11. Cembrzynska-Nowak, M., Szklarz, E., Inglot, A.D., Teodorczyk-Injeyan, J.A. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis 1993, 147(2): 291-295
12. Shealy, D., Cai, A., Nesspor, T. et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNF-alpha. Arthritis Rheum 2007, 56(9, Suppl.): Abst 274.
13. Shealy, D., Cai, A., Lacy, E. et al., Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNF-alpha. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0088.
14. Zhou, H., Jang, H., Fleischmann, R.M. et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007, 47(3): 383-396 (Pubitemid 46294717)
15. Shealy, D.J., Visvanathan, S. Anti-TNF antibodies: Lessons from the past, roadmap for the future. Handb Exp Pharmacol 2008, 181: 101-129
16. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., Kollias, G. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991, 10(13): 4025-4031
17. Xu, Z., Wang, Q., Zhuang, Y. et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol 2009, Nov 25 [Epub ahead of print].
18. Kay, J., Matteson, E.L., Dasgupta, B. et al. Golimumab in patients with active meumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008, 58(4): 964-975 (Pubitemid 351563997)
19. Xu, Z., Lee, H., Vu, T. et al. Population pharmacokinetics of golimumab: A human anti-tumor necrosis factor-alpha monoclonal antibody, in patients with rheumatoid arthritis. 37th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 14-16, Philadelphia) 2008, Abst 61.
20. Xu, Z., Vu, T., Lee, H. et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 2009, 49(9): 1056-1070
21. Xu, Z.; Vu, T., Lee, H., Hu, C. et al. Population pharmacokinetics of golimumab, a human anti-tumor necrosis factor-alpha monoclonal antibody-in patients with ankylosing spondylitis. 37th Annu Meet Am Coll Clin Pharmacol (ACCP) (September 14-16, Philadelphia) 2008, Abst 59.
22. Bhagat, S., Dasgupta, B., Rahman, M.U. Golimumab: a new anti-TNF agent on the horizon for inflammatory arthritis. Int J Clin Rheumatol 2009, 4(1): 15-23.
23. Herman, S., Krönke, C., Schett, G. Molecular mechanisms of inflammatory bone damage: Emerging targets for therapy. Trends Mol Med 2008, 14(6): 245-253
24. Helmick, C.G., Felson, D.T., Lawrence, R.C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58(1): 15-25.
25. Visvanathan, S., Rojas, J., Wagner, C. et al. Decreases in E-selectin, IL-18, SAA, & MMP-9 may predict clinical response to golimumab + MTX therapy in RA patients. Rheumatology (Oxford) 2008, 47(Suppl. 2): Abst 131.
26. Emery, P., Fleischmann, R.M., Moreland, L.W. et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active meumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009, 60(8): 2272-2283
27. Keystone, E.C., Genovese, M.C., Klareskog, L. et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. Ann Rheum Dis 2009, 68(6): 789-796
28. Smolen, J.S., Kay, J., Doyle, M.K. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374(9685): 210-221
29. Buchanan, J., Fleischmann, R., Genovese, M.C. et al. Golimumab significantly improves self-reported productivity in patients with rheumatoid arthritis: Results from three phase III studies. 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 1027.
30. Buchanan, J., Emery, P., Keystone, E.C. et al. Golimumab significantly reduces time lost from work for patients with rheumatoid arthritis: Pooled results from three phase 3 studies. 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 824.
31. Golimumab in rheumatoid arthritis patients with an inadequate response to etanercept (Enbrel) or adalimumab (Humira) (NCT01004432). ClinicalTrials.gov Web Site 2009, October 29.
32. An efficacy and safety study of intravenous golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate, non steroidal pain medications and/or corticosteroids (NCT00973479). ClinicalTrials.gov Web Site 2009, September 4.
33. Subcutaneous golimumab (GLM) plus DMARDs for rheumatoid arthritis, followed by intravenous/subcutaneous GLM strategy (P06129AM1) (GO-MORE), (NCT00975130). ClinicalTrials.gov Web Site 2009, August 20.
34. Boumpas, D.T., Illei, G.G., Tassiulas, I.O. Psoriatic Arthritis. In: Primer on the Rheumatic Diseases. J.H. Klippel, L.J. Crofford, J.H. Stone, C.M. Weyand (Eds.) Atlanta, Ga 2001, 233-8.
35. Ritchlin, C., Haas-Smith, S.A., Hicks, D., Cappuccio, J., Osterland, C.K., Looney, R.J. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25(8): 1544-1552
36. Antoni, C.E., Kavanaugh, A., Kirkham, B. et al. Sustained benefits of infliximab therapy for dermatologie and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52(4):1227-1236
37. Mease, P.J., Gladman, D.D., Ritchlin, C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52(10): 3279-89.
38. Gladman, D.D., Antoni, C., Mease, P., Clegg, D.O., Nash, P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64(Suppl. 2): ii14-ii17.
39. Kavanaugh, A., Mclnnes, I., Mease, P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60(4):976-986
40. Kavanaugh, A., Mease, P., Krueger, G.G. et al. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: Fifty two-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 671.
41. Kavanaugh, A., Mease, P., Krueger, G.G. et al. Golimumab, a new, human, TNF alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2008, 67(Suppl. 2): Abst OP-0161.
42. McInnes, I., Mease, P., Kreueger, G. et al. Golimumab administered subcutanelously every 4 weeks in psoriatic arthritis: 52-week efficacy and safety results of the GO-REVEAL study. Rheumatology (Oxford) 2009, 48 (Suppl. 1): Abst OP22.
43. Kavanaugh, A., Mease, P., Krueger, G.G., Gladman, D., Gomez-Reino, J.J., Papp, K. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis: Fifty two-week efficacy and safety results of the GO-REVEAL study. Intern Med J 2009, 39(Suppl. 2): Abst P14.
44. Inman, R.D., Davis, J.C., Jr., Heijde, D.V. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008, 58(11): 3402-3412
45. Van Der Heijde, D., Deodhar, A., Braun, J. et al. Golimumab significantly improves health-related quality of life in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. Ann Rheum Dis 2008, 67(Suppl. 2): Abst SAT0274.
46. Van Der Heijde, D., Braun, J., Davis, J.C., Jr. et al. Head-to-head comparison of 3 enthesitis indices in the ankylosing spondylitis anti-TNF-alpha trial of golimumab (GO-RAISE). Ann Rheum Dis 2008, 67(Suppl. 2): Abst SAT0272.
47. Van Der Heijde, D., Braun, J., Davis, J.C., Jr. et al. Head-to-head comparison of three enthesitis indices in the ankylosing spondylitis anti-TNF-alpha trial of golimumab (GO-RAISE). 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 530.
48. Braun, J., Inman, R., Van Der Heijde, D. et al. Golimumab significantly improves productivity in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. Ann Rheum Dis 2008, 67(Suppl. 2): Abst FRI0306.
49. Braun, J., Inman, R.D., Van Der Heijde, D. et al. Golimumab significantly improves productivity in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 1113.
50. Braun, J.; Inman, R.D.; Van Der Heijde, D. et al. Golimumab significantly Improves productivity in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. 6th Int Congr Spondyloarthropathies (October 2-4, Gent) 2008, Abst P55.
51. Deodhar, A., Braun, J., Inman, R.D. et al. Golimumab significantly improves sleep in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. Ann Rheum Dis 2008, 67(Suppl. 2): Abst FRI0314.
52. Deodhar, A., Braun, J., Inman, R.D. et al. Golimumab significantly improves sleep in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. 6th Int Congr Spondyloarthropathies (October 2-4, Gent) 2008, Abst P85.
53. Buchanan, J., Hsu, B., Gathany, T., Parasuraman, S. Improving functionality improves sleep in patients with acute ankylosing spondylitis: Results from the GO-RAISE study. 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 1115.
54. Van Der Heijde, D., Deodhar, A., Braun, J. et al. Golimumab significantly improves health-related quality of life in patients with active ankylosing spondylitis: Results from the phase 3 GO-RAISE study. 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 1114.
55. Furst, D.E., Doyle, M.K., Kay, J. et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody administered subcutaneously every 4 weeks, improves anemia and well-being in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. 72nd Annu Sci Meet Am Coll Rheumatol (October 24-29, San Francisco) 2008, Abst 1019.
56. Furst, D.E., Doyle, M.K., Kay, J. et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody administered subcutaneously every 4 weeks, improves anemia and well-being in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Ann Rheum Dis 2008, 67(Suppl. 2): Abst THU0143.
57. Wenzel, S.E., Barnes, P.J., Bleecker, E.R. et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179(7): 549-558
58. A study of the safety and effectiveness of CNTO 148 (golimumab) in patients with moderately to severely active ulcerative colitis (NCT00487S39). ClinicalTrials.gov Web Site 2007, June 14.
59. A study of the safety and effectiveness of CNTO 148 (golimumab) in patients with moderately to severely active ulcerative colitis (CR014179) (NCT00488631). ClinicalTrials.gov Web Site 2007, June 18.
60. Phase 2, multicenter, randomized, double-blind, parallel-group, placebo-controlled study evaluating the safety and efficacy of treatment with ustekinumab or golimumab in subjects with chronic sarcoidosis (NCT00955279). ClinicalTrials.gov Web Site 2009, August 6.